Boston Scientific Corporation
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-51.1% vs price
Base Case (Median)
-33.0% vs price
Bull Case (75th pct.)
0.8% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $15.76 | -69.4% | High (40%) |
| PE Comparable | $54.75 | 6.4% | Medium (25%) |
| Growth Trajectory DCF | $95.19 | 85.1% | Medium (20%) |
| Graham Number | $30.10 | -41.5% | Medium (40%) |
| EV/EBITDA | $34.46 | -33.0% | Medium (20%) |
| EV/FCF | $48.97 | -4.8% | Medium (20%) |
| Earnings Power Value | $20.25 | -60.6% | Medium (50%) |
Based on 7 out of 8 methods, BSX appears fairly valued at the current price of $51.43. The base case fair value of $34.46 implies 33.0% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.